(Z)-Ligustilide is a phthalide constituent strongly associated with lovage, angelica, and Ligusticum-type root aromatics rather than mainstream fragrance terpenes. In the AromaForge archive it is a dominant marker of lovage root oil, where it helps define the oil's character far more than a trace constituent would. The live evidence base is stronger for identity, occurrence, and preclinical mechanism work than for human outcomes, with accessible studies repeatedly pointing to inflammatory-signaling, oxidative-stress, and neuroprotection models. That makes this a chemistry-forward profile with meaningful early-stage bioactivity literature, but not a basis for medical claims.
Chemical identity and composition
PubChem resolves ligustilide under CID 5319022 with formula C12H14O2 and an isomer-aware synonym set that includes (Z)-Ligustilide, cis-ligustilide, and CAS 81944-09-4. In the local archive it is the lead constituent of lovage root oil at 61.79%, which fits the broader literature describing ligustilide as a major lipophilic phthalide in Apiaceae medicinal roots. The literature also repeatedly notes that ligustilide is chemically reactive and not always stable, which matters when translating bench findings into formulation or storage assumptions.
Aroma and practical use
- Use the recorded celery-like, herbaceous, rooty, spicy, oily descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2012 RAW264.7 macrophage study reported that (Z)-ligustilide dose-dependently reduced LPS-induced iNOS and COX-2 expression and down-regulated NF-kB, p38 MAPK, ERK, and JNK signaling.
The paper directly tested isolated (Z)-ligustilide rather than only a whole extract, making it one of the clearer mechanism-linked inflammation studies for this constituent.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2006 mouse forebrain-ischemia study found lower infarct volume, lower malondialdehyde, higher glutathione peroxidase and SOD activity, and more favorable Bcl-2/Bax/caspase-3 markers after ligustilide treatment.
This is preclinical neuroprotection evidence and should be framed as model-based rather than as established human neurological benefit.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A full-text PMC study concluded that ligustilide diminished inflammatory mediator production, acted at the transcriptional level, and targeted NF-kB-linked inflammatory signaling in macrophages and leukocytes.
The paper also compared ligustilide with the anti-inflammatory prostaglandin 15d-PGJ2 and argued that they share several biological response features in inflammatory cell systems.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
The strongest accessible human-facing source in this pass was a pharmacokinetics and pharmacology review rather than a dedicated fragrance-safety assessment or clinical tolerability trial.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Review literature describes poor oral bioavailability and substantial first-pass metabolism in rats, which reinforces that pharmacology findings do not translate cleanly into predictable human exposure outcomes.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the literature emphasizes instability and reactivity of ligustilide, formulation or storage claims should stay conservative unless batch-specific stability data exist.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
suppression of NF-kB and MAPK inflammatory signaling
A 2012 macrophage study reported that (Z)-ligustilide reduced iNOS and COX-2 expression and inhibited IκBα degradation together with p38, ERK, and JNK phosphorylation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
reduction of inflammatory mediator production in leukocyte and macrophage systems
An open-access PMC study found lower NO, PGE2, cytokine, and chemokine output after ligustilide exposure and linked the effect to transcription-level regulation of inflammatory pathways.
This experimental finding does not establish benefit, dose or safety in people using this blend.
antioxidant and anti-apoptotic signaling in cerebral ischemia models
The mouse forebrain-ischemia study associated ligustilide with lower malondialdehyde, higher SOD and glutathione peroxidase activity, increased Bcl-2, and reduced Bax and caspase-3 immunoreactivity.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- This pass did not verify a high-quality human clinical trial on isolated (Z)-ligustilide.
- No constituent-specific IFRA limit or fragrance-safety assessment PDF was verified in the reviewed public sources.
- Public literature often comes from herbal-medicine contexts rather than inhalation or topical aroma-use contexts, so translation into aromatics copy should remain conservative.
- Two further searches for IFRA/RIFM/Tisserand dermal-limit data for (Z)-ligustilide (81944-09-4) were also inconclusive; the previous 0.8% dermal_limit_pct placeholder had no traceable citation and has been removed.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.